Total Payments
$505,524
2024 Payments
$84,817
Companies
35
Transactions
1,205
Medicare Patients
1,119
Medicare Billing
$143,371
Payment Breakdown by Category
Research$244,230 (48.3%)
Other$165,330 (32.7%)
Consulting$35,468 (7.0%)
Travel$32,982 (6.5%)
Food & Beverage$27,209 (5.4%)
Education$305.28 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $244,230 | 44 | 48.3% |
| Honoraria | $92,683 | 41 | 18.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,648 | 58 | 14.4% |
| Consulting Fee | $35,468 | 21 | 7.0% |
| Travel and Lodging | $32,982 | 88 | 6.5% |
| Food and Beverage | $27,209 | 944 | 5.4% |
| Education | $305.28 | 9 | 0.1% |
Payments by Type
General
$261,294
1,161 transactions
Research
$244,230
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CSL Behring | $412,016 | 371 | $0 (2024) |
| BioCryst US Sales Co., LLC | $40,005 | 101 | $0 (2024) |
| Shire North American Group Inc | $16,790 | 52 | $0 (2019) |
| BioCryst Pharmaceuticals, Inc. | $12,050 | 33 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,754 | 85 | $0 (2024) |
| Pharming Healthcare, Inc. | $4,778 | 37 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,093 | 97 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,978 | 134 | $0 (2024) |
| GENZYME CORPORATION | $1,349 | 68 | $0 (2024) |
| Optinose US, Inc. | $1,243 | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $84,817 | 219 | CSL Behring ($51,238) |
| 2023 | $47,377 | 207 | CSL Behring ($41,456) |
| 2022 | $14,107 | 149 | CSL Behring ($8,738) |
| 2021 | $59,218 | 145 | CSL Behring ($46,998) |
| 2020 | $16,178 | 70 | CSL Behring ($5,366) |
| 2019 | $42,334 | 154 | CSL Behring ($18,670) |
| 2018 | $56,779 | 148 | CSL Behring ($55,820) |
| 2017 | $184,715 | 113 | CSL Behring ($183,729) |
All Payment Transactions
1,205 individual payment records from CMS Open Payments — Page 1 of 49
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $354.80 | General |
| 12/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $29.43 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,645.10 | General |
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $629.30 | General |
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $0.69 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/11/2024 | CSL Behring | — | — | Cash or cash equivalent | $2,186.60 | Research |
| Study: An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | ||||||
| 12/10/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $29.85 | General |
| Category: Immunology and Neurology | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $31.37 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: IMMUNOLOGY | ||||||
| 11/29/2024 | Cycle Pharmaceuticals Inc | SAJAZIR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,220.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | CSL Behring | — | — | Cash or cash equivalent | $1,890.42 | Research |
| Study: An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | ||||||
| 11/25/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $30.70 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $2.73 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $38.58 | General |
| Category: DERMATOLOGY | ||||||
| 11/20/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $12.44 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: BIOLOGIC | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $32.31 | General |
| Category: RESPIRATORY | ||||||
| 11/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $33.57 | General |
| Category: GENETIC DISEASE | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.37 | General |
| Category: Immunology | ||||||
| 10/28/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/27/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $134.64 | General |
| Category: BIOLOGIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema | CSL Behring | $149,275 | 13 |
| An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | CSL Behring | $88,536 | 15 |
| A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | CSL Behring | $5,700 | 1 |
| A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema | CSL Behring | $719.25 | 15 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 373 | 2,692 | $119,628 | $48,722 |
| 2022 | 6 | 282 | 1,559 | $89,141 | $36,963 |
| 2021 | 6 | 271 | 1,416 | $89,437 | $35,751 |
| 2020 | 4 | 193 | 403 | $55,897 | $21,935 |
Total Patients
1,119
Total Services
6,070
Medicare Billing
$143,371
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 148 | 317 | $43,512 | $21,536 | 49.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 85 | $20,890 | $7,957 | 38.1% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 26 | 1,998 | $19,980 | $7,101 | 35.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $9,794 | $4,414 | 45.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 47 | 47 | $10,660 | $4,079 | 38.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 56 | 148 | $14,060 | $3,185 | 22.7% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 11 | 61 | $732.00 | $450.96 | 61.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 128 | 310 | $40,449 | $20,990 | 51.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 38 | 51 | $14,810 | $4,791 | 32.3% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 14 | 1,061 | $10,610 | $3,738 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $7,322 | $3,169 | 43.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 34 | 34 | $8,540 | $2,417 | 28.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 43 | 78 | $7,410 | $1,858 | 25.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 117 | 280 | $38,298 | $19,035 | 49.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 37 | 37 | $12,293 | $4,452 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 47 | $15,062 | $3,814 | 25.3% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 13 | 931 | $9,310 | $3,475 | 37.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 29 | 29 | $5,734 | $2,532 | 44.2% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 40 | 92 | $8,740 | $2,442 | 27.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 108 | 262 | $34,522 | $15,334 | 44.4% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2020 | 42 | 90 | $8,550 | $2,545 | 29.8% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 31 | 31 | $5,899 | $2,441 | 41.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 12 | 20 | $6,926 | $1,615 | 23.3% |
About Dr. Donald Levy, MD
Dr. Donald Levy, MD is a Allergy & Immunology healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518055011.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donald Levy, MD has received a total of $505,524 in payments from pharmaceutical and medical device companies, with $84,817 received in 2024. These payments were reported across 1,205 transactions from 35 companies. The most common payment nature is "" ($244,230).
As a Medicare-enrolled provider, Levy has provided services to 1,119 Medicare beneficiaries, totaling 6,070 services with total Medicare billing of $143,371. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Orange, CA
- Active Since 10/10/2006
- Last Updated 07/08/2007
- Taxonomy Code 207K00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1518055011
Products in Payments
- Haegarda (Biological) $231,241
- Berinert (Biological) $80,170
- ORLADEYO (Drug) $23,798
- CINRYZE (Drug) $17,346
- Orladeyo (Drug) $10,085
- RUCONEST (Biological) $4,778
- Hizentra (Biological) $4,644
- Privigen (Biological) $3,725
- TAKHZYRO (Biological) $2,679
- DUPIXENT (Biological) $2,397
- TRELEGY ELLIPTA (Drug) $1,256
- Xhance (Drug) $1,243
- SAJAZIR (Drug) $1,220
- Xembify (Biological) $550.60
- CUVITRU (Biological) $534.56
- FASENRA (Biological) $481.94
- BREZTRI (Drug) $420.17
- HYQVIA (Biological) $378.43
- BREO (Drug) $363.83
- NUCALA (Biological) $348.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Orange
Dr. Anita Kohli-Pamnani, M.d, M.D
Allergy & Immunology — Payments: $29,071
Allergy & Immunology $29,071
Dr. Wan-Yin Chan, M.d, M.D
Allergy & Immunology — Payments: $19,243
Allergy & Immunology $19,243
Dr. Stanley Galant, Md, MD
Allergy & Immunology — Payments: $16,846
Allergy & Immunology $16,846
Dr. Chao-I Lin, Md, MD
Allergy & Immunology — Payments: $15,316
Allergy & Immunology $15,316
Dr. William Harris, Md, MD
Allergy & Immunology — Payments: $13,779
Allergy & Immunology $13,779
Jason Wong
Allergy & Immunology — Payments: $774.51
Allergy & Immunology $774.51